Seroprevalence of SARS-Cov-2 in the Setting of a Non-dedicated COVID-19 Hospital in a Low CoV-2 Incidence Area: Implications for Surgery

Overview

We have herein analysed the patients admitted to our Department that underwent serologic tests for SARS-CoV-2 either by Ab or RT PCR, to estimate the prevalence of COVID-19 in the setting of a non-dedicated COVID-19 hospital and in a low CoV-2 incidence area, and to evaluate if security measures are necessary for this context.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: April 30, 2020

Interventions

  • Diagnostic Test: SARS-CoV-2 Ab
    • Patient test for specific antibodies for SARS-CoV-2

Arms, Groups and Cohorts

  • Hospitalized patients

Clinical Trial Outcome Measures

Primary Measures

  • Seroprevalence of SARS-CoV-2
    • Time Frame: 3 months
    • Positivity of specific IgM or IgG

Participating in This Clinical Trial

Inclusion Criteria

  • Patients hospitalized during pandemic spread Exclusion Criteria:

  • Incomplete data

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • University of Cagliari
  • Provider of Information About this Clinical Study
    • Principal Investigator: Fabio Medas, Assistant Professor – University of Cagliari

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.